Gotham Asset Management LLC Has $28.19 Million Stock Holdings in Becton, Dickinson and Company $BDX

Gotham Asset Management LLC grew its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 59.4% in the third quarter, according to the company in its most recent filing with the SEC. The firm owned 150,592 shares of the medical instruments supplier’s stock after acquiring an additional 56,138 shares during the quarter. Gotham Asset Management LLC owned about 0.05% of Becton, Dickinson and Company worth $28,186,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of the stock. Focus Financial Network Inc. grew its stake in Becton, Dickinson and Company by 2.2% during the third quarter. Focus Financial Network Inc. now owns 2,692 shares of the medical instruments supplier’s stock worth $504,000 after buying an additional 58 shares in the last quarter. Phillips Wealth Planners LLC lifted its holdings in shares of Becton, Dickinson and Company by 2.7% during the 3rd quarter. Phillips Wealth Planners LLC now owns 2,241 shares of the medical instruments supplier’s stock worth $430,000 after acquiring an additional 58 shares during the period. CX Institutional boosted its position in shares of Becton, Dickinson and Company by 3.6% during the 3rd quarter. CX Institutional now owns 1,731 shares of the medical instruments supplier’s stock worth $324,000 after acquiring an additional 60 shares in the last quarter. KCM Investment Advisors LLC increased its stake in Becton, Dickinson and Company by 4.1% in the third quarter. KCM Investment Advisors LLC now owns 1,525 shares of the medical instruments supplier’s stock valued at $285,000 after acquiring an additional 60 shares during the last quarter. Finally, Gamco Investors INC. ET AL increased its stake in Becton, Dickinson and Company by 0.6% in the third quarter. Gamco Investors INC. ET AL now owns 9,570 shares of the medical instruments supplier’s stock valued at $1,791,000 after acquiring an additional 60 shares during the last quarter. Institutional investors own 86.97% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have weighed in on BDX shares. Piper Sandler reaffirmed a “neutral” rating and issued a $170.00 target price (down from $205.00) on shares of Becton, Dickinson and Company in a report on Tuesday, February 10th. Barclays started coverage on Becton, Dickinson and Company in a research report on Tuesday, February 10th. They set an “overweight” rating and a $202.00 price objective for the company. Jefferies Financial Group decreased their target price on Becton, Dickinson and Company from $220.00 to $190.00 and set a “buy” rating on the stock in a research report on Tuesday, February 10th. Citigroup dropped their target price on shares of Becton, Dickinson and Company from $233.00 to $232.00 and set a “buy” rating for the company in a report on Tuesday, February 10th. Finally, TD Cowen raised their price target on shares of Becton, Dickinson and Company from $183.00 to $189.00 and gave the company a “hold” rating in a research note on Wednesday, February 11th. Five equities research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Becton, Dickinson and Company presently has an average rating of “Hold” and a consensus price target of $195.46.

Becton, Dickinson and Company Trading Up 0.5%

Shares of BDX stock opened at $160.19 on Tuesday. Becton, Dickinson and Company has a twelve month low of $127.59 and a twelve month high of $187.35. The stock’s fifty day simple moving average is $189.23 and its 200 day simple moving average is $189.75. The company has a quick ratio of 0.58, a current ratio of 1.05 and a debt-to-equity ratio of 0.67. The firm has a market capitalization of $45.61 billion, a P/E ratio of 26.13, a P/E/G ratio of 11.55 and a beta of 0.24.

Becton, Dickinson and Company (NYSE:BDX) last posted its earnings results on Monday, February 9th. The medical instruments supplier reported $2.91 EPS for the quarter, beating the consensus estimate of $2.81 by $0.10. Becton, Dickinson and Company had a return on equity of 15.76% and a net margin of 8.01%.The firm had revenue of $5.25 billion during the quarter, compared to the consensus estimate of $5.15 billion. During the same period last year, the company earned $3.43 earnings per share. The business’s quarterly revenue was up 1.6% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2026 guidance at 12.350-12.650 EPS. As a group, sell-side analysts predict that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 31st. Investors of record on Tuesday, March 10th will be given a dividend of $1.05 per share. The ex-dividend date is Tuesday, March 10th. This represents a $4.20 annualized dividend and a yield of 2.6%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is currently 68.52%.

Becton, Dickinson and Company announced that its Board of Directors has authorized a stock repurchase plan on Tuesday, January 27th that authorizes the company to repurchase $10.00 million in shares. This repurchase authorization authorizes the medical instruments supplier to buy up to 0% of its shares through open market purchases. Shares repurchase plans are typically an indication that the company’s management believes its stock is undervalued.

Insider Buying and Selling

In other news, EVP Michael David Garrison sold 1,610 shares of Becton, Dickinson and Company stock in a transaction on Thursday, January 15th. The shares were sold at an average price of $207.46, for a total transaction of $334,010.60. Following the transaction, the executive vice president owned 12,095 shares in the company, valued at approximately $2,509,228.70. The trade was a 11.75% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Bertram L. Scott sold 953 shares of the business’s stock in a transaction on Wednesday, February 18th. The stock was sold at an average price of $182.61, for a total transaction of $174,027.33. Following the completion of the sale, the director directly owned 36,763 shares in the company, valued at approximately $6,713,291.43. This represents a 2.53% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 3,416 shares of company stock worth $674,693 over the last three months. Insiders own 0.40% of the company’s stock.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.